Amarantus Bioscience Holdings Inc (AMBS)

[jugs]

Biotech companies typically run up huge debts as they develop their business models and proceed to actualize their business plans. Lacking a working history with profits to fund acquisition and ongoing operations, these companies have no choice but to negotiate plans by which they can exchange equity (part ownership in the company) for operating capital to be used while creating a viable business entity.

Such is the case with Amarantus which is acquiring companies with promising drugs in their pipelines. Is there anything dilutive happening? Yes, certainly---although we should deny its impact if we believe said acquisitions will prove accretive in the shorter term. This is akin to my asking you to fund a project I might have in mind that will enable me to repay you threefold down the road.

There is nothing shady in this. In fact, it is so routine it is standard procedure.

When I see attempts to denigrate a company in which I've invested substantial capital as is the case with AMBS, I'm reminded of what I'm seeing of value in this company and I shudder to think that others might be scared away.

Amarantus has a legitimate claim to an increasingly sizable number of products designed to alleviate pain, stress and numerous other forms of pain none could or would wish upon another. I praise our company for pursuing such fine ideals and am proud to be a shareholder.